Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2016 pubmed 118 citations

LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity.

Fabisiak. Adam A; Murawska. Natalia N; Fichna. Jakub J

Key Findings

  • LL-37 acts as a broad‑spectrum antimicrobial peptide.
  • It has strong chemotactic and immunomodulatory effects.
  • Potential therapeutic applications are discussed for immune, respiratory, gastrointestinal, and skin systems.

Practical Outcomes

  • The review highlights LL-37’s promise as a drug candidate, but it doesn’t provide dosing guidelines or ready‑to‑use protocols. For biohackers, the main takeaway is that LL-37 is still in early research stages and not yet suitable for safe self‑experimentation.

Summary

LL-37 is a natural human peptide that kills germs and also helps steer the immune system. Scientists think it could be useful for treating skin problems, lung issues, gut disorders, and immune‑related diseases, but the paper is just a review and doesn’t give specific ways to use it.

Abstract

Antimicrobial peptides (AMPs) is a large family of compounds serving as natural antibiotics, widely distributed across the organism, mainly in mucus layers. They are designed to prevent pathogens from colonization. Among them, defensins and cathelicidins could be found. LL-37, the sole human cathelicidin draws particular attention because of its outstanding abilities. In addition to being a broad spectrum antibiotic, LL-37 has potent chemotactic and immunomodulatory properties. In this review, we discussed the potency of LL-37 as a therapeutic agent in four systems: immunological, respiratory, gastrointestinal and in the skin. We analyzed the main molecular pathways dependent on human cathelicidin and related them to specific diseases. We conclude that LL-37 shows a great potential to be further investigated and developed as a drug with clinical use.

Study Information

Provider

pubmed

Year

2016

Date

2016-04-07T00:00:00.000Z

DOI

10.1016/j.pharep.2016.03.015

Citations

118

References

90